US Broker Ratings

CeriBell, Inc. (CBLL) Stock Analysis: Analysts See 32.94% Upside Potential in Innovative Medical Technology

CeriBell, Inc. (CBLL), a dynamic player in the healthcare sector specializing in medical devices, is capturing investor attention with its cutting-edge approach to acute care diagnostics. Based in Sunnyvale, California,..

Keros Therapeutics, Inc. (KROS) Stock Analysis: Exploring a Potential 92.59% Upside in the Biotech Industry

Keros Therapeutics, Inc. (NASDAQ: KROS), a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, is capturing the attention of investors with its promising pipeline and significant potential upside. Specializing in the..

Bicara Therapeutics Inc. (BCAX) Stock Analysis: Assessing a 27% Upside Potential for this Biotech Innovator

Bicara Therapeutics Inc. (NASDAQ: BCAX) offers a compelling narrative in the biotechnology sector, commanding attention with its innovative approach to solid tumor treatment and a promising upside potential. With a..

Fulgent Genetics, Inc. (FLGT) Investor Outlook: Uncovering a 50.86% Potential Upside in the Diagnostics Sector

Fulgent Genetics, Inc. (NASDAQ: FLGT) stands at a fascinating juncture within the healthcare sector, particularly in the diagnostics and research industry. With a market capitalization of approximately $503.75 million, this..

KalVista Pharmaceuticals (KALV): A Biotech Gem with 75% Upside Potential

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is emerging as an intriguing opportunity in the biotech sector, capturing investor attention with its promising pipeline and significant upside potential. With a focus on..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Promising Biotech with 12.48% Potential Upside

Enliven Therapeutics, Inc. (NASDAQ: ELVN), a burgeoning player in the biotechnology sector, is capturing the attention of investors with its promising pipeline of cancer treatment drugs. With a market capitalization..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring the 547% Potential Upside

Anavex Life Sciences Corp. (NASDAQ: AVXL) presents an intriguing opportunity for investors in the biotech sector, particularly given its remarkable potential upside of 547.06%. This New York-based company is making..

Praxis Precision Medicines, Inc. (PRAX) Stock Analysis: A Biotech with Nearly 100% Upside Potential

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, has captured the attention of investors with its focus on innovative therapies for central nervous system (CNS) disorders. With an..

Iovance Biotherapeutics (IOVA) Stock Analysis: A 137% Potential Upside Sparks Investor Interest

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is capturing the attention of savvy investors, thanks to a promising potential upside of 136.84% based on the average analyst target price. Known for its..

Nutex Health Inc. (NUTX) Stock Analysis: Capitalizing on a Potential 117.83% Upside in Healthcare

Nutex Health Inc. (NASDAQ: NUTX) has emerged as a compelling player in the healthcare sector, particularly within the medical care facilities industry. With a market capitalization of $719.64 million, the..

Rocket Pharmaceuticals, Inc. (RCKT)

⚠️ No article content returned.

..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Exploring a 64% Upside Potential in the Healthcare Sector

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) stands out in the healthcare sector with its focus on pain management solutions, a vital niche within the drug manufacturing industry. Based in the United..

Neuropace, Inc. (NPCE) Stock Analysis: A Healthcare Innovator with a Promising 28% Potential Upside

Investors looking to tap into the burgeoning healthcare sector might want to take a closer look at Neuropace, Inc. (NASDAQ: NPCE), a trailblazer in the medical device industry. With its..

Dianthus Therapeutics, Inc. (DNTH) Stock Analysis: Exploring a 35% Upside Potential Amid Biotech Innovations

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a clinical-stage biotechnology company, is attracting significant investor attention due to its promising pipeline aimed at treating severe autoimmune diseases. With a current market capitalization..

Arbutus Biopharma (ABUS) Stock Analysis: Unveiling an 11.5% Upside in the Biotech Sector

Arbutus Biopharma Corporation (NASDAQ: ABUS) stands as a significant player in the biotechnology sector, capturing investor attention with its focus on developing novel therapeutics for infectious diseases. With a current..

AbCellera Biologics Inc. (ABCL)

⚠️ No article content returned.

..

Taysha Gene Therapies, Inc. (TSHA) Investor Outlook: Exploring a Potential 94% Upside in the Biotech Arena

Taysha Gene Therapies, Inc. (TSHA), a clinical-stage biotechnology company, is gaining attention in the healthcare sector with its ambitious pursuit of adeno-associated virus-based gene therapies. Headquartered in Dallas, Texas, and..

ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring a 38.82% Upside Potential in the Biotech Sector

ArriVent BioPharma, Inc. (AVBP), a clinical-stage biopharmaceutical company, is making waves in the biotechnology industry with its promising pipeline of cancer therapies. With a market capitalization of $1.31 billion, ArriVent..

Spyre Therapeutics, Inc. (SYRE) Investor Outlook: Exploring a 22% Potential Upside in the Biotech Sector

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a promising player in the biotechnology sector, stands out with a compelling potential upside of 22.53%, catching the attention of investors seeking opportunities in the..

Simulations Plus, Inc. (SLP) Stock Analysis: Exploring a 67.61% Potential Upside in Healthcare Software Solutions

Simulations Plus, Inc. (NASDAQ: SLP) stands prominently in the healthcare sector, specializing in health information services. This U.S.-based company has carved a niche in the drug discovery and development sector..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds